Rhenman & Partners Asset Management AB Buys Diplomat Pharmacy Inc, Cigna Corp, Alexion Pharmaceuticals Inc, Sells Express Scripts Holding Co, Nektar Therapeutics Inc, Loxo Oncology Inc

• New Purchases: MD, PDCO,
• Added Positions: DPLO, CI, ALXN, AERI, BIIB, EXEL, ABBV, ALNY, CVS, IOVA,
• Reduced Positions: NKTR, LOXO, HZNP, WBA, AGN, BMY, HUM, GILD, PTLA, AET,
• Sold Out: ESRX, JNJ, ACAD,

For the details of Rhenman & Partners Asset Management AB's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Rhenman+%26+Partners+Asset+Management+AB

1. Cigna Corp (CI) - 174,691 shares, 3.65% of the total portfolio. Shares added by 33.97%
2. CVS Health Corp (CVS) - 438,868 shares, 3.46% of the total portfolio. Shares added by 17.39%
3. Alexion Pharmaceuticals Inc (ALXN) - 243,329 shares, 3.39% of the total portfolio. Shares added by 26.82%
4. Vertex Pharmaceuticals Inc (VRTX) - 142,465 shares, 2.75% of the total portfolio. Shares reduced by 8.09%
5. Incyte Corp (INCY) - 376,916 shares, 2.61% of the total portfolio. Shares reduced by 1.78%

Rhenman & Partners Asset Management AB initiated holding in Mednax Inc. The purchase prices were between $42.76 and $48.58, with an estimated average price of $45.91. The stock is now traded at around $46.30. The impact to a portfolio due to this purchase was 0.58%. The holding were 124,674 shares as of 2018-09-30.

Rhenman & Partners Asset Management AB initiated holding in Patterson Companies Inc. The purchase prices were between $22.28 and $25.67, with an estimated average price of $23.7. The stock is now traded at around $23.86. The impact to a portfolio due to this purchase was 0.09%. The holding were 38,500 shares as of 2018-09-30.

Rhenman & Partners Asset Management AB added to a holding in Diplomat Pharmacy Inc by 724.94%. The purchase prices were between $18.61 and $27.08, with an estimated average price of $21.29. The stock is now traded at around $19.24. The impact to a portfolio due to this purchase was 2%. The holding were 1,174,411 shares as of 2018-09-30.

Rhenman & Partners Asset Management AB added to a holding in Cigna Corp by 33.97%. The purchase prices were between $169.03 and $208.25, with an estimated average price of $185.38. The stock is now traded at around $211.95. The impact to a portfolio due to this purchase was 0.93%. The holding were 174,691 shares as of 2018-09-30.

Rhenman & Partners Asset Management AB added to a holding in Alexion Pharmaceuticals Inc by 26.82%. The purchase prices were between $115.32 and $139.01, with an estimated average price of $125.44. The stock is now traded at around $135.27. The impact to a portfolio due to this purchase was 0.72%. The holding were 243,329 shares as of 2018-09-30.

Rhenman & Partners Asset Management AB added to a holding in Aerie Pharmaceuticals Inc by 157.14%. The purchase prices were between $56.15 and $73.9, with an estimated average price of $64.28. The stock is now traded at around $59.60. The impact to a portfolio due to this purchase was 0.68%. The holding were 180,000 shares as of 2018-09-30.

Rhenman & Partners Asset Management AB added to a holding in Biogen Inc by 130.77%. The purchase prices were between $293.51 and $383.83, with an estimated average price of $344.3. The stock is now traded at around $347.23. The impact to a portfolio due to this purchase was 0.6%. The holding were 30,000 shares as of 2018-09-30.

Rhenman & Partners Asset Management AB added to a holding in AbbVie Inc by 85.71%. The purchase prices were between $88.91 and $98.84, with an estimated average price of $94.83. The stock is now traded at around $95.84. The impact to a portfolio due to this purchase was 0.57%. The holding were 130,000 shares as of 2018-09-30.

Rhenman & Partners Asset Management AB sold out a holding in Express Scripts Holding Co. The sale prices were between $74.44 and $95.23, with an estimated average price of $85.24.

Rhenman & Partners Asset Management AB sold out a holding in Johnson & Johnson. The sale prices were between $121.58 and $142.88, with an estimated average price of $132.89.

Rhenman & Partners Asset Management AB sold out a holding in ACADIA Pharmaceuticals Inc. The sale prices were between $13.03 and $21.81, with an estimated average price of $15.73.